Webinar Replay: Bioreactor Scale-up Principles for Viral Vector Production

Webinar Replay: Bioreactor Scale-up Principles for Viral Vector Production

Bioreactor Scale-up Principles for Viral Vector Production

Scaling viral vector production from development scale to larger stirred-tank bioreactors requires more than increasing volume. Parameters such as oxygen transfer, mixing, shear forces, and power input interact in ways that directly influence yield, critical quality attributes, and overall process performance. In this technical webinar, NecstGen shares a structured approach to scale-up based on engineering principles.

If you missed the live session, you can now watch the full webinar on demand.

What you’ll learn:

  • How oxygen transfer changes with scale and how to compare surface aeration and sparging strategies in viral vector processes.

  • How to interpret and apply kLa as a practical scale-up parameter rather than a theoretical value.

  • How power input influences mixing, oxygen transfer, and shear, and how to balance these parameters during scale-up.

  • How agitation and aeration contribute to shear stress, particularly for shear-sensitive viral vectors.

  • How to approach scale-up decisions systematically to support reproducibility and GMP-readiness.

This replay is relevant for process development scientists, engineers, and manufacturing teams who want to strengthen the technical foundation of their viral vector scale-up strategy and reduce variability when moving toward GMP production.

If you have additional questions, we invite you to share your questions.

Webinar Improving Lentiviral Vector Yield with 2G UNic™ Technology

Webinar Improving Lentiviral Vector Yield with 2G UNic™ Technology

Improving Lentiviral Vector Yield with 2G UNic™ Technology

Lentiviral vectors (LVs) are indispensable for ex vivo gene therapies, but producing them at scale while maintaining high quality and yield remains a major challenge. In this expert-led webinar, you’ll learn how NecstGen and ProteoNic are tackling this issue together.

If you missed the live session, you can now watch the full webinar on demand.

What you’ll learn:

  • A practical overview of the lentiviral production process, from seed train to downstream processing.

  • Common bottlenecks that cap LV titers—despite optimal transfection conditions.

  • How ProteoNic’s 2G UNic™ technology enhances translational efficiency in host cells to improve LV yield.

  • Real-world results and insights from Maurice van der Heijden (ProteoNic) and Diederik Lokhorst (NecstGen).

Whether you’re troubleshooting your own production process or exploring next-gen tools to boost yields and reduce costs, this replay offers valuable technical insights into overcoming a key barrier in gene therapy manufacturing.

If you have additional questions, we invite you to share your questions.

Webinar Reducing Lentivirus Costs

Webinar Reducing Lentivirus Costs

Reducing Lentivirus Costs

Are you curious about how cost reductions in Cell & Gene Therapy manufacturing can be achieved? 

Key areas of focus include:

If you missed our recent webinar on Reducing Lentivirus Costs: A DOE Case Study, you can now watch the replay and gain valuable insights into cost-efficiency strategies for Cell & Gene Therapy manufacturing.

Lentiviral vectors (LV) play a critical role in CAR T therapies, but the high cost of plasmid DNA used in transfection-based production remains a significant challenge. During the webinar, Diederik Lokhorst, Viral Vector Specialist at NecstGen, shared how our team leverages Design of Experiments (DOE) to address this challenge, reduce the Cost of Goods (COG), and make lentivirus-based therapies more affordable.

What You’ll Learn in the Replay:
– An inside look at transfection-based lentivirus production

– ⁠DOE as a tool to understand and improve your manufacturing process

– ⁠A Case study applying DOE to reduce LV Manufacturing Costs for CAR T

If you have additional questions, we invite you to share your questions.

Webinar LV Process for CAR T

Webinar LV Process for CAR T

Transforming Your LV Process For CAR T

Shifting from traditional, ad hoc methodologies to a structured, data-based development approach to create a scalable, GMP-ready process

Key areas of focus include:

Transitioning from research to clinical application presents numerous challenges, particularly for CAR T developers, academic institutions, and small companies at a pivotal point in their development journey. This webinar is specifically designed to address these groups, aiming to refine their process development for clinical readiness. We will emphasise the need for a shift to a structured, data-driven methodology, crucial for meeting the stringent requirements of large-scale Good Manufacturing Practice (GMP).

Our objective?

To help you understand the necessity of shifting from traditional, ad hoc methodologies to a structured, data-based development approach. This segment emphasises the importance of embracing change and innovation to overcome the limitations of the “this is how we’ve always done it” mindset.

– Quality by Design (QbD): a systematic development framework
– Design of Experiments (DOE): understanding and improving your process
– Scalability: designing a process that can be scaled up from the bench to large, industrial scale
– USP & DSP: improving production and purification

Our expert can provide insights and answer your queries to advance your CAR T therapy development.

If you have additional questions, we invite you to share your questions.

NecstGen Services

Cell Therapy Development & Manufacturing

Viral Vector Development & Manufacturing

Cleanroom Rental

Consultancy

About Us

NecstGen is a non-profit CDMO and Centre of Excellence for Cell and Gene Therapy located in a purpose-built GMP facility in Leiden, The Netherlands. Dedicated to the field of Cell and Gene Therapies, we provide expertise and capacity.

About Us

Partners

History

Facility

Ecosystem